spacer
spacer

PDBsum entry 1yc0

Go to PDB code: 
protein ligands Protein-protein interface(s) links
Hydrolase/inhibitor PDB id
1yc0

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
247 a.a. *
66 a.a. *
Ligands
PO4
Waters ×119
* Residue conservation analysis
PDB id:
1yc0
Name: Hydrolase/inhibitor
Title: Short form hgfa with first kunitz domain from hai-1
Structure: Hepatocyte growth factor activator. Chain: a. Fragment: sequence database residues 373-655. Synonym: hgf activator, hgfa. Engineered: yes. Kunitz-type protease inhibitor 1. Chain: i. Fragment: sequence database residues 245-303. Synonym: hepatocyte growth factor activator inhibitor type 1, hai-1,
Source: Homo sapiens. Human. Organism_taxid: 9606. Gene: hgfac. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108. Gene: spint1, hai1. Expressed in: escherichia coli. Expression_system_taxid: 562.
Biol. unit: Dimer (from PQS)
Resolution:
2.60Å     R-factor:   0.196     R-free:   0.218
Authors: S.Shia,J.Stamos,D.Kirchhofer,B.Fan,J.Wu,R.T.Corpuz,L.Santell, R.A.Lazarus,C.Eigenbrot
Key ref:
S.Shia et al. (2005). Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B. J Mol Biol, 346, 1335-1349. PubMed id: 15713485 DOI: 10.1016/j.jmb.2004.12.048
Date:
21-Dec-04     Release date:   15-Feb-05    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
Q04756  (HGFA_HUMAN) -  Hepatocyte growth factor activator from Homo sapiens
Seq:
Struc:
 
Seq:
Struc:
655 a.a.
247 a.a.
Protein chain
Pfam   ArchSchema ?
O43278  (SPIT1_HUMAN) -  Kunitz-type protease inhibitor 1 from Homo sapiens
Seq:
Struc:
 
Seq:
Struc:
529 a.a.
66 a.a.*
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 7 residue positions (black crosses)

 Enzyme reactions 
   Enzyme class: Chain A: E.C.3.4.21.-  - ?????
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]

 

 
DOI no: 10.1016/j.jmb.2004.12.048 J Mol Biol 346:1335-1349 (2005)
PubMed id: 15713485  
 
 
Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
S.Shia, J.Stamos, D.Kirchhofer, B.Fan, J.Wu, R.T.Corpuz, L.Santell, R.A.Lazarus, C.Eigenbrot.
 
  ABSTRACT  
 
Hepatocyte growth factor activator (HGFA) is a serine protease that converts hepatocyte growth factor (HGF) into its active form. When activated HGF binds its cognate receptor Met, cellular signals lead to cell growth, differentiation, and migration, activities which promote tissue regeneration in liver, kidney and skin. Intervention in the conversion of HGF to its active form has the potential to provide therapeutic benefit where HGF/Met activity is associated with tumorigenesis. To help identify ways to moderate HGF/Met effects, we have determined the molecular structure of the protease domain of HGFA. The structure we determined, at 2.7 A resolution, with no pseudo-substrate or inhibitor bound is characterized by an unconventional conformation of key residues in the enzyme active site. In order to find whether this apparently non-enzymatically competent arrangement would persist in the presence of a strongly-interacting inhibitor, we also have determined, at 2.6 A resolution, the X-ray structure of HGFA complexed with the first Kunitz domain (KD1) from the physiological inhibitor hepatocyte growth factor activator inhibitor 1B (HAI-1B). In this complex we observe a rearranged substrate binding cleft that closely mirrors the cleft of other serine proteases, suggesting an extreme conformational dynamism. We also characterize the inhibition of 16 serine proteases by KD1, finding that the previously reported enzyme specificity of the intact extracellular region of HAI-1B resides in KD1 alone. We find that HGFA, matriptase, hepsin, plasma kallikrein and trypsin are potently inhibited, and use the complex structure to rationalize the structural basis of these results.
 
  Selected figure(s)  
 
Figure 1.
Figure 1. Uninhibited HGFA. Schematic representation of the crystallized HGFA 34 kDa fragment (starting at residue 373), looking into the substrate binding/active site region. Disulfide links are labeled. Cys168 was modeled with two side-chain conformations, only one of which makes a bond to Cys182. Cys187 is unpaired. An eight-residue section of the HGFA light chain (green) can be seen in the rear, including its disulfide link to the protease domain (Cys394/Cys122). Loops colored pink differ structurally among homologous enzymes and help determine inhibitor and substrate specificity. The crystallized construct in the context of intact HGFA is depicted at the bottom. Molecular images produced using PyMOL (Delano Scientific, San Carlos CA).
Figure 5.
Figure 5. The HGFA/KD1 complex. (a) The conventional conformation of the HGFA substrate binding region from the HAI-1-KD1 complex (light brown) compared to the unconventional conformation from uninhibited HGFA (blue). (b) Overall view with HGFA surface (light brown/red) and KD1 (green/yellow), including side-chains form Arg13(258), Arg15(260), and Phe18(263). The (N-terminal affinity tag + KD1) construct in the context of HAI-1B is depicted at the bottom. Prominent residues from the HGFA 37-loop, 60-loop and 99-loop are labeled. Red and yellow colors are residues of HGFA (red) and KD1 (yellow) with an atom within 3.5 Å of the other protein. (c) Details of the interaction between HGFA and HAI-1-KD1, in the same orientation as above. Portions of the KD1 domain (yellow) are depicted in the HGFA (light brown) active site. H-bonds between KD1 and HGFA are grey/black dotted lines. Inhibitor residue labels are underlined.
 
  The above figures are reprinted by permission from Elsevier: J Mol Biol (2005, 346, 1335-1349) copyright 2005.  
  Figures were selected by an automated process.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
20672321 M.Tripathi, A.A.Potdar, H.Yamashita, B.Weidow, P.T.Cummings, D.Kirchhofer, and V.Quaranta (2011).
Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.
  Prostate, 71, 184-196.  
20809655 A.D.Vogt, A.Bah, and E.Di Cera (2010).
Evidence of the E*-E equilibrium from rapid kinetics of Na+ binding to activated protein C and factor Xa.
  J Phys Chem B, 114, 16125-16130.  
20402765 C.Eigenbrot, R.Ganesan, and D.Kirchhofer (2010).
Hepatocyte growth factor activator (HGFA): molecular structure and interactions with HGFA inhibitor-1 (HAI-1).
  FEBS J, 277, 2215-2222.  
20704569 R.Ganesan, C.Eigenbrot, and D.Kirchhofer (2010).
Structural and mechanistic insight into how antibodies inhibit serine proteases.
  Biochem J, 430, 179-189.  
20974933 Z.Chen, L.A.Pelc, and E.Di Cera (2010).
Crystal structure of prethrombin-1.
  Proc Natl Acad Sci U S A, 107, 19278-19283.
PDB code: 3nxp
19473969 A.Bah, C.J.Carrell, Z.Chen, P.S.Gandhi, and E.Di Cera (2009).
Stabilization of the E* form turns thrombin into an anticoagulant.
  J Biol Chem, 284, 20034-20040.
PDB code: 3gic
19496715 A.Giubellino, W.M.Linehan, and D.P.Bottaro (2009).
Targeting the Met signaling pathway in renal cancer.
  Expert Rev Anticancer Ther, 9, 785-793.  
19180666 E.Di Cera (2009).
Serine proteases.
  IUBMB Life, 61, 510-515.  
19586901 P.S.Gandhi, M.J.Page, Z.Chen, L.Bush-Pelc, and E.Di Cera (2009).
Mechanism of the anticoagulant activity of thrombin mutant W215A/E217A.
  J Biol Chem, 284, 24098-24105.
PDB codes: 3hk3 3hk6 3hki 3hkj
20004165 R.Ganesan, C.Eigenbrot, Y.Wu, W.C.Liang, S.Shia, M.T.Lipari, and D.Kirchhofer (2009).
Unraveling the allosteric mechanism of serine protease inhibition by an antibody.
  Structure, 17, 1614-1624.
PDB codes: 2wub 2wuc 3k2u
18263585 A.Désilets, F.Béliveau, G.Vandal, F.O.McDuff, P.Lavigne, and R.Leduc (2008).
Mutation G827R in matriptase causing autosomal recessive ichthyosis with hypotrichosis yields an inactive protease.
  J Biol Chem, 283, 10535-10542.  
18794723 K.Sexton, D.Balharry, and K.A.BéruBé (2008).
Genomic biomarkers of pulmonary exposure to tobacco smoke components.
  Pharmacogenet Genomics, 18, 853-860.  
18784072 M.Tripathi, S.Nandana, H.Yamashita, R.Ganesan, D.Kirchhofer, and V.Quaranta (2008).
Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.
  J Biol Chem, 283, 30576-30584.  
17089378 R.E.Saunders, C.Abarrategui-Garrido, V.Frémeaux-Bacchi, E.Goicoechea de Jorge, T.H.Goodship, M.López Trascasa, M.Noris, I.M.Ponce Castro, G.Remuzzi, S.Rodríguez de Córdoba, P.Sánchez-Corral, C.Skerka, P.F.Zipfel, and S.J.Perkins (2007).
The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.
  Hum Mutat, 28, 222-234.  
18077410 Y.Wu, C.Eigenbrot, W.C.Liang, S.Stawicki, S.Shia, B.Fan, R.Ganesan, M.T.Lipari, and D.Kirchhofer (2007).
Structural insight into distinct mechanisms of protease inhibition by antibodies.
  Proc Natl Acad Sci U S A, 104, 19784-19789.
PDB codes: 2r0k 2r0l
16557597 C.Parr, and W.G.Jiang (2006).
Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
  Int J Cancer, 119, 1176-1183.  
16908524 P.Moran, W.Li, B.Fan, R.Vij, C.Eigenbrot, and D.Kirchhofer (2006).
Pro-urokinase-type plasminogen activator is a substrate for hepsin.
  J Biol Chem, 281, 30439-30446.  
16103126 B.Fan, T.D.Wu, W.Li, and D.Kirchhofer (2005).
Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostasin.
  J Biol Chem, 280, 34513-34520.  
  15972969 B.S.Knudsen, J.M.Lucas, L.Fazli, S.Hawley, S.Falcon, I.M.Coleman, D.B.Martin, C.Xu, L.D.True, M.E.Gleave, P.S.Nelson, and G.E.Ayala (2005).
Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate.
  Am J Pathol, 167, 255-266.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB code is shown on the right.

 

spacer

spacer